Eli Lilly and Company, Indianapolis, IN, USA.
J Med Econ. 2011;14(6):705-8. doi: 10.3111/13696998.2011.613505. Epub 2011 Sep 5.
The objective of this study was to examine the frequency of hypoglycemia among patients with type 2 diabetes who had concomitantly used exenatide BID (exenatide) and long-acting insulin and continued this combination vs those who continued long-acting insulin alone.
Retrospective analyses, using a large managed care database, were used to estimate the frequency of hypoglycemia (episodes/patient/6 months) for patients who concomitantly used exenatide and long-acting insulin during a 6-month follow-up period.
From among 2082 patients on concomitant exenatide and long-acting insulin, those who continued this combination (n=472) had a lower frequency of hypoglycemia compared to those who remained on long-acting insulin alone (n=312) (0.03 ± 1.9 vs 0.10 ± 1.01 [episodes/patient/6 months]; p<0.0001).
Only hypoglycemia that required medical intervention (coded for hypoglycemia) was captured. The study could not evaluate any association between insulin dose titration and hypoglycemia or examine other outcomes such as HbA1c, weight, and body mass index, due to lack of data availability.
Patients who concomitantly used exenatide BID and long-acting insulin experienced a lower rate of hypoglycemia.
本研究旨在考察同时使用艾塞那肽双时相（艾塞那肽）和长效胰岛素的 2 型糖尿病患者发生低血糖的频率，并与继续单独使用长效胰岛素的患者进行比较。
利用大型管理式医疗数据库进行回顾性分析，以评估在 6 个月的随访期间同时使用艾塞那肽和长效胰岛素的患者低血糖（发作/患者/6 个月）的频率。
在 2082 名同时使用艾塞那肽和长效胰岛素的患者中，继续使用这种联合治疗的患者（n=472）低血糖的频率低于继续单独使用长效胰岛素的患者（n=312）（0.03±1.9 与 0.10±1.01[发作/患者/6 个月]；p<0.0001）。
仅捕获了需要医疗干预（编码为低血糖）的低血糖。由于缺乏数据可用性，本研究无法评估胰岛素剂量滴定与低血糖之间的任何关联，也无法评估其他结果，如 HbA1c、体重和体重指数。
同时使用艾塞那肽双时相和长效胰岛素的患者低血糖发生率较低。
